Arkadios Wealth Advisors Acquires 3,880 Shares of Cencora, Inc. $COR

Arkadios Wealth Advisors raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 29.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,849 shares of the company’s stock after buying an additional 3,880 shares during the quarter. Arkadios Wealth Advisors’ holdings in Cencora were worth $5,266,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC raised its stake in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC grew its position in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the last quarter. Caldwell Trust Co bought a new position in shares of Cencora during the 2nd quarter worth about $46,000. Salomon & Ludwin LLC increased its holdings in shares of Cencora by 638.1% during the 3rd quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock worth $47,000 after purchasing an additional 134 shares during the period. Finally, Capital A Wealth Management LLC raised its position in shares of Cencora by 3,975.0% during the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after buying an additional 159 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $343.45, for a total value of $1,750,221.20. Following the completion of the transaction, the chief executive officer owned 68,059 shares of the company’s stock, valued at approximately $23,374,863.55. The trade was a 6.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 15,220 shares of company stock worth $5,343,561 in the last three months. Insiders own 10.80% of the company’s stock.

Cencora Stock Down 1.2%

COR opened at $350.72 on Wednesday. The firm has a market cap of $68.04 billion, a price-to-earnings ratio of 44.12, a PEG ratio of 1.69 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The firm’s 50-day simple moving average is $349.16 and its 200-day simple moving average is $321.12. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Analysts Set New Price Targets

A number of research firms recently weighed in on COR. UBS Group lifted their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. TD Cowen raised their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. JPMorgan Chase & Co. lifted their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Finally, Mizuho upped their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $381.42.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.